Literature DB >> 10781859

Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).

K Matsuo1, T Yoshikawa, H Asanuma, T Iwasaki, Y Hagiwara, Z Chen, S E Kadowaki, H Tsujimoto, T Kurata, S I Tamura.   

Abstract

Inactivated influenza vaccine was administered intranasally to BALB/c mice together with an adjuvant (cholera toxin B subunit [CTB] supplemented with a trace amount of the whole toxin, CTB*) and its ability to induce innate immunity and confer protection against influenza was examined. Nasal wash virus titres 3 days after inoculation of homologous viruses were measured as an index of the ability of the vaccine to confer protection in mice immunized with either CTB*-combined vaccine or CTB* alone 1-21 days previously. The results were as follows. (1) Partial but significant reduction of the nasal-wash virus titres (prevention) was detected beginning 3 days after the vaccination, that is, 2 days earlier than the appearance of both virus-specific antibody-forming cells (AFCs) in the nasal-associated lymphoid tissue (NALT) and virus-specific IgA antibody responses in the nasal washes of mice immunized with the CTB*-combined vaccine. (2) The protection, detected on day 3 and peaking on day 5 but lost by day 21, was also conferred in mice immunized with CTB* alone. (3) The non-specific prevention was detected at doses of more than 0.3 microg of CTB*/mouse. (4) The nonspecific protection beginning 3 days after the immunization involved the enhanced expression of cytokine mRNAs (IL-15 and IL-18), considered responsible for natural killer (NK) cell activation, by the non-T cell populations in the NALT. (5) Normal NALT cells, when cultured in vitro with CTB*, secreted IL-1beta within a few hours in culture. These results demonstrate that the CTB*-combined vaccine, when given intranasally into mice, can confer nonspecific protection against influenza beginning 3 days after the vaccination and that CTB* also possessed this ability to confer protection non-specifically and temporarily by inducing the secretion of IL-1beta, one of the most important cytokines that initiates both innate and adaptive immunity, and also NK cell activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781859     DOI: 10.1016/s0264-410x(00)00055-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.

Authors:  F C Pimenta; E N Miyaji; A P M Arêas; M L S Oliveira; A L S S de Andrade; P L Ho; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

2.  Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

Authors:  Carole Balmelli; Stéphane Demotz; Hans Acha-Orbea; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.

Authors:  Saúl Rojas-Hernández; Marco A Rodríguez-Monroy; Rubén López-Revilla; Aldo A Reséndiz-Albor; Leticia Moreno-Fierros
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 4.  Nonthermal plasma as part of a novel strategy for vaccination.

Authors:  Hager Mohamed; Rita A Esposito; Michele A Kutzler; Brian Wigdahl; Fred C Krebs; Vandana Miller
Journal:  Plasma Process Polym       Date:  2020-07-13       Impact factor: 3.877

5.  Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.

Authors:  Minami Nagai; Miyu Moriyama; Takeshi Ichinohe
Journal:  mBio       Date:  2021-08-17       Impact factor: 7.867

6.  Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.

Authors:  Andrew S Herbert; Lynn Heffron; Roy Sundick; Paul C Roberts
Journal:  Virol J       Date:  2009-04-24       Impact factor: 4.099

7.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.

Authors:  Krystyna Mozdzanowska; Darya Zharikova; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Virol J       Date:  2007-10-31       Impact factor: 4.099

8.  FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.

Authors:  Ali A Ashkar; Karen L Mossman; Brian K Coombes; Carlton L Gyles; Randy Mackenzie
Journal:  PLoS Pathog       Date:  2008-12-05       Impact factor: 6.823

9.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.